🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Insiders Buy Around $112M Of 3 Stocks

Published 15/02/2022, 11:55
© Reuters.  Insiders Buy Around $112M Of 3 Stocks
IXIC
-
INCY
-
TWOU
-
I1NC34
-
VERA
-

US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Incyte (NASDAQ:INCY)

  • The Trade: Incyte Corporation (NASDAQ: INCY) Director Felix Baker acquired a total of 1,598,374 shares at an average price of $66.91. To acquire these shares, it cost around $106.95 million.
  • What’s Happening: Incyte recently posted Q4 adjusted EPS of $0.10, compared to $0.93 posted a year ago.
  • What Incyte Does: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis.
Vera Therapeutics
  • The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Maha Katabi acquired a total of 266,666 shares at an average price of $15.00. To acquire these shares, it cost around $4 million.
  • What’s Happening: Vera Therapeutics recently priced an upsized offering of common stock at $15 per share.
  • What Vera Therapeutics Does: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases.
Also check this: 3 Penny Stocks Insiders Are Buying

2U

  • The Trade: 2U, Inc. (NASDAQ: TWOU) Director Paul Maeder bought a total of 110,000 shares at an average price of $9.43. To acquire these shares, it cost around $1.04 million.
  • What’s Happening: 2U recently reported Q4 earnings results and issued FY22 revenue guidance.
  • What 2U Does: 2U Inc provides educational technology services for nonprofit colleges and universities. It builds, delivers, and monitors educational platforms that enable online delivery of degree programs and alternative credentials such as short technical courses.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.